The Artificial Liver Support System (ALSS) in Patients With Acute on Chronic Liver Failure - Combined Molecular Adsorption System With Double Plasma (DPMAS) and Therapeutic Plasma Exchange (TPE) and Its Effects on Coagulation and Vital Organ Function

What this Trial Is About

Researchers are evaluating the artificial liver support system (ALSS) for patients with acute on chronic liver failure (ACLF) or acute liver failure (ALF). The study aims to assess the effects of a combined molecular adsorption system with double plasma (DPMAS) and therapeutic plasma exchange (TPE) on primary blood clotting, inflammation, and the function of vital organs. This approach seeks to improve clinical conditions and support liver regeneration or prepare patients for liver transplantation. Participants are divided into two groups: one receives ALSS therapy alongside standard care, and the other receives standard care alone without ALSS. ALSS sessions involve alternating treatments with DPMAS and TPE, conducted for up to 7 to 10 days or until liver transplantation or recovery of liver function. The study does not involve randomization or masking. During the study, participants will be monitored for survival without liver transplant at 21 days after the first ALSS session, along with overall survival rates at 21 and 90 days. Researchers will also track the liver transplantation rate and timing within 90 days. The study involves hospitalized patients in intensive care units and includes assessments of organ function and coagulation. Participants may be followed up through day 28 and beyond for outcome evaluations.

ALSS - DPMAS and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation, Inflammation and the Function of Vital Organs in ALF or ACLF